5-Amino-1MQ is a small chemical molecule, not a peptide — even though it is often mentioned in the same breath as weight-loss peptides. It blocks an enzyme called NNMT, which inside the fat cell consumes vitamin B3 and the molecule that carries methyl groups. Blocking that enzyme in mouse studies reduced fat tissue without reducing food intake, and that single finding is the whole reason for the interest. The evidence, however, is entirely preclinical: not one human study has been published, and the ClinicalTrials.gov registry holds no registered trial of 5-Amino-1MQ or of any other NNMT inhibitor. Below we set out exactly what has been shown and where the knowledge stops.
What 5-Amino-1MQ is
The name is shorthand for the chemistry: a molecule built around a quinolinium ring with an amino group attached. It was described in 2018 by a group at the University of Texas Medical Branch in Galveston as one of a series of “NNMT inhibitors” — compounds that block the work of a particular enzyme. It is not a medicine, it has no marketing authorisation and it has been through no phase of clinical testing. One common error is worth correcting straight away: 5-Amino-1MQ is not a peptide, that is, it is not a chain of amino acids — it is an ordinary small molecule, like most drugs that come as tablets.
How it works — the NNMT enzyme in plain terms
NNMT stands for nicotinamide N-methyltransferase. The enzyme takes hold of two things at once: nicotinamide (one form of vitamin B3) and SAM, the molecule that hands out “methyl groups” inside the cell — small chemical tags that steer how genes behave. It sticks them together and releases a product called 1-MNA.
The trouble is that nicotinamide is the raw material for NAD+, the molecule without which a cell cannot burn fuel. The more work NNMT does, the less nicotinamide returns to the NAD+ cycle and the less SAM is left for everything else. The enzyme therefore acts like a tax levied on two of the cell's key resources. In the fat tissue and liver of obese and diabetic mice, NNMT is clearly raised. The idea behind 5-Amino-1MQ is simple: block the tax and let both resources rebuild on their own.
Where the idea came from — the 2014 Nature paper
The starting point was not this molecule but a gene. In 2014 Barbara Kahn's group at Harvard published a paper in Nature in which NNMT turned out to be the gene whose activity shifted most strongly in the fat tissue of mice with disrupted glucose transport. Silencing that gene in fat tissue and liver (by targeted gene knockdown, not with a drug) protected the mice against obesity caused by a fatty diet, thanks to greater energy expenditure; in fat tissue, SAM and NAD+ levels rose and fat cells consumed more oxygen. It was this paper that turned NNMT into a drug target. 5-Amino-1MQ is an attempt to hit that target with a molecule rather than with genetic manipulation.
What was studied — cells
The 2018 paper looked first at cultured fat cells. 5-Amino-1MQ crossed cell membranes well and was selective: it did not block related methyl-transferring enzymes, nor the enzyme that rebuilds NAD+. In fat cells it lowered the level of the reaction product (1-MNA) to about 40% of baseline, suppressed fat formation and raised intracellular NAD+ — by roughly 1.2 to 1.6 times, although across the full series of concentrations the effect was only borderline significant (p = 0.0568) and just one measurement point reached significance. SAM rose at the higher concentrations. This detail matters: the figure of “+34% NAD+” that circulates online does not come from this paper — the original contains no such value.
What was studied — animals
The best-known experiment: obese mice fed a fatty diet for 16 weeks received subcutaneous injections of 5-Amino-1MQ for 11 days. Over that period the control group gained 0.6 g (about 1.4% of starting weight) while the treated group lost 2.0 g (about 5.1%). The mass of epididymal fat tissue fell by roughly 35%, the size of an individual fat cell by more than 30%, and total plasma cholesterol by about 30%. The key observation: the amount of food eaten did not change (28.1 g in the control group against 26.2 g in the treated one), which suggests the weight loss came from altered metabolism rather than from a smaller appetite. The authors reported no signs of toxicity.
A more recent paper from 2024 extended dosing to 28 days. The compound dose-dependently limited gains in weight and fat mass, improved the oral glucose tolerance test and insulin sensitivity, and brought down excessive insulin. In the liver, fatty infiltration and inflammatory-cell infiltration both decreased, triglycerides fell, and liver enzymes returned to normal. A separate 2021 paper asked what happens when an NNMT inhibitor is combined with a switch to a lean diet: body composition and liver fat returned to the values seen in healthy control mice, which the diet alone did not achieve.
Muscle in old mice — the second line of research
The same group also studied NNMT inhibitors in muscle. In 24-month-old (very old) mice with an injury to the shin muscle, the compound activated muscle stem cells: the cross-section of the rebuilt fibres was almost twice as large, and peak contractile force rose by about 70% against controls. The 2024 paper compared the inhibitor with intensive exercise in mice aged 22 to 24 months: sedentary mice given the compound had roughly 40% greater grip strength, exercising mice 20%, and the two combined 60%. It sounds spectacular — but it concerns mice, and translating an “exercise mimetic” from rodent to human has failed before (the same lesson as with AICAR).
How it behaves in the body
The only published data on the fate of the compound in a living body come from rats. After oral and intravenous dosing, researchers measured how much reached the bloodstream: oral bioavailability was 38.4%, with a half-life of 3.8 hours after intravenous and 6.9 hours after oral administration. That confirms the molecule is absorbed from the gut — but in a rat, not in a human. The 2024 paper also showed that after subcutaneous dosing the compound distributes into fat tissue, muscle and liver. In the pivotal 2018 experiment, however, it was given by injection, not by mouth.
No human studies — what that means
We searched two independent registries. In PubMed, the terms “5-amino-1MQ”, “5-AMQ” and the full chemical name return a handful of papers in total, all laboratory or animal work; none describes administration to a person. ClinicalTrials.gov holds not a single registered trial of this compound, and a query for NNMT inhibitors as an intervention returns zero results. A 2026 review in Trends in Pharmacological Sciences confirms this outright: twelve years after the Nature paper, no NNMT inhibitor has entered clinical testing, the obstacles being insufficient target engagement, poor bioavailability and unknown safety profiles.
The practical conclusion is unambiguous: no dose that is “effective in humans” exists, because no study capable of establishing one has been run. The figures circulating online are conversions from milligrams per kilogram in mice, and that arithmetic is no substitute for a phase-one trial. We deliberately give no methods of use and no doses.
Safety and the limits of the evidence
Nothing is known about safety in humans. Rodent work reported no signs of toxicity, but those studies ran for 11 and 28 days; there are no data on longer dosing in any species. A separate question concerns the mechanism: NNMT consumes SAM, the molecule that governs methylation, one of the basic ways genes are switched on and off. Permanently raising the SAM pool means interfering with that system, and the long-term consequences have not been studied. NNMT is also strongly raised in many cancers, where blocking it is being explored as a therapy — which shows how widely the enzyme is woven into cell metabolism.
A second serious weakness: almost the entire literature on 5-Amino-1MQ comes from a single centre and the company linked to it. The authors declare this in their papers (the founder of, and employees at, a firm developing NNMT inhibitors). Independent replication in another laboratory is missing. The exception is the 2014 Nature paper — but that concerns gene silencing, not this molecule.
The wider context — the NAD+ fashion
5-Amino-1MQ belongs to a broader family of ideas along the lines of “raise NAD+ and metabolism will repair itself”. Other approaches supply precursors, the substances a cell builds NAD+ from; we covered those in our piece on NAD+, NMN and NR. The difference is fundamental: precursors add raw material, whereas an NNMT inhibitor closes the tap through which the raw material escapes. It is worth noting, though, that the precursor branch already has human trials and meta-analyses behind it, and the functional results proved disappointing. That is a warning for 5-Amino-1MQ: a biochemical effect in a rodent does not automatically become a clinical effect in a person.
Summary
5-Amino-1MQ is a small molecule that blocks the NNMT enzyme; it is not a peptide. The data from cells and rodents are consistent and interesting: less fat tissue without eating less, better glucose handling, a less fatty liver, stronger muscles in old mice. All of it concerns animals, most of it comes from a single research centre, and none of it has ever been tested in a person — neither in a publication nor in a registered clinical trial. As things stand this is a promising preclinical hypothesis, not an agent with confirmed effects in humans.
Sources
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152. PMID: 29155147. DOI: 10.1016/j.bcp.2017.11.007. pubmed.ncbi.nlm.nih.gov/29155147
- Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26(11):5272–5282. PMID: 39161060. DOI: 10.1111/dom.15879. pubmed.ncbi.nlm.nih.gov/39161060
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262. PMID: 24717514. DOI: 10.1038/nature13198. pubmed.ncbi.nlm.nih.gov/24717514
- Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports. 2021;11(1):5637. PMID: 33707534. DOI: 10.1038/s41598-021-85051-6. pubmed.ncbi.nlm.nih.gov/33707534
- Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports. 2024;14(1):15554. PMID: 38969654. DOI: 10.1038/s41598-024-66034-9. pubmed.ncbi.nlm.nih.gov/38969654
- Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481–492. PMID: 30753815. DOI: 10.1016/j.bcp.2019.02.008. pubmed.ncbi.nlm.nih.gov/30753815
- Awosemo O, Neelakantan H, Watowich S, et al. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis. 2021;204:114255. PMID: 34304009. DOI: 10.1016/j.jpba.2021.114255. pubmed.ncbi.nlm.nih.gov/34304009
- Puleo N, Allega MF, Niemann CU, Lengyel E. Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation. Trends in Pharmacological Sciences. 2026;47(6):638–654. PMID: 42067476. DOI: 10.1016/j.tips.2026.04.002. pubmed.ncbi.nlm.nih.gov/42067476
For in-vitro laboratory research only. It is not a human medicine and is not for treatment.